(Total Views: 641)
Posted On: 03/26/2021 10:35:47 AM
Post# of 148908
Misleading? Today on Seeking Alpha...GSK & VIR CV19 Therapeutic..
The companies have applied the EUA for VIR-7831 to treat those with mild-to-moderate COVID-19 who are at risk for progression to hospitalization or death. The EUA submission is backed by the positive results from the Phase 3 COMET-ICE trial which showed an 85% (p=0.002) reduction in hospitalization or death in patients receiving VIR-7831 as monotherapy.
my response:
Reduction in deaths 85% when treating mild/moderate? I don't understand. Don't many or even most m/m recover on their own without any treatment? They may have treated a large number of patients, but it would seem to me that a very small % of m/m placebo patients would die and a tiny % of deaths for the treated group. Maybe it is explained by the "at risk for progression to hospitalization or death" thus, older folks with additional health issues?
The companies have applied the EUA for VIR-7831 to treat those with mild-to-moderate COVID-19 who are at risk for progression to hospitalization or death. The EUA submission is backed by the positive results from the Phase 3 COMET-ICE trial which showed an 85% (p=0.002) reduction in hospitalization or death in patients receiving VIR-7831 as monotherapy.
my response:
Reduction in deaths 85% when treating mild/moderate? I don't understand. Don't many or even most m/m recover on their own without any treatment? They may have treated a large number of patients, but it would seem to me that a very small % of m/m placebo patients would die and a tiny % of deaths for the treated group. Maybe it is explained by the "at risk for progression to hospitalization or death" thus, older folks with additional health issues?
(5)
(0)Scroll down for more posts ▼
